204 related articles for article (PubMed ID: 29428273)
1. High Sustained Antibody Titers in Patients with Classic Infantile Pompe Disease Following Immunomodulation at Start of Enzyme Replacement Therapy.
Poelman E; Hoogeveen-Westerveld M; Kroos-de Haan MA; van den Hout JMP; Bronsema KJ; van de Merbel NC; van der Ploeg AT; Pijnappel WWMP
J Pediatr; 2018 Apr; 195():236-243.e3. PubMed ID: 29428273
[TBL] [Abstract][Full Text] [Related]
2. B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease.
Elder ME; Nayak S; Collins SW; Lawson LA; Kelley JS; Herzog RW; Modica RF; Lew J; Lawrence RM; Byrne BJ
J Pediatr; 2013 Sep; 163(3):847-54.e1. PubMed ID: 23601496
[TBL] [Abstract][Full Text] [Related]
3. High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient.
Rairikar M; Kazi ZB; Desai A; Walters C; Rosenberg A; Kishnani PS
Mol Genet Metab; 2017 Sep; 122(1-2):76-79. PubMed ID: 28648664
[TBL] [Abstract][Full Text] [Related]
4. Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long-term clinical outcome of classic infantile Pompe patients.
Poelman E; van den Dorpel JJA; Hoogeveen-Westerveld M; van den Hout JMP; van der Giessen LJ; van der Beek NAME; Pijnappel WWMP; van der Ploeg AT
J Inherit Metab Dis; 2020 Nov; 43(6):1243-1253. PubMed ID: 32506446
[TBL] [Abstract][Full Text] [Related]
5. Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort.
Desai AK; Baloh CH; Sleasman JW; Rosenberg AS; Kishnani PS
Front Immunol; 2020; 11():1727. PubMed ID: 32849613
[TBL] [Abstract][Full Text] [Related]
6. Effects of immunomodulation in classic infantile Pompe patients with high antibody titers.
Poelman E; Hoogeveen-Westerveld M; van den Hout JMP; Bredius RGM; Lankester AC; Driessen GJA; Kamphuis SSM; Pijnappel WWM; van der Ploeg AT
Orphanet J Rare Dis; 2019 Mar; 14(1):71. PubMed ID: 30902109
[TBL] [Abstract][Full Text] [Related]
7. Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy.
Chen HA; Hsu RH; Fang CY; Desai AK; Lee NC; Hwu WL; Tsai FJ; Kishnani PS; Chien YH
Front Immunol; 2024; 15():1336599. PubMed ID: 38715621
[TBL] [Abstract][Full Text] [Related]
8. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease.
Banugaria SG; Prater SN; Ng YK; Kobori JA; Finkel RS; Ladda RL; Chen YT; Rosenberg AS; Kishnani PS
Genet Med; 2011 Aug; 13(8):729-36. PubMed ID: 21637107
[TBL] [Abstract][Full Text] [Related]
9. A Race Against Time-Changing the Natural History of CRIM Negative Infantile Pompe Disease.
Gupta P; Shayota BJ; Desai AK; Kiblawi F; Myridakis D; Messina J; Tah P; Tambini-King L; Kishnani PS
Front Immunol; 2020; 11():1929. PubMed ID: 33013846
[TBL] [Abstract][Full Text] [Related]
10. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.
Messinger YH; Mendelsohn NJ; Rhead W; Dimmock D; Hershkovitz E; Champion M; Jones SA; Olson R; White A; Wells C; Bali D; Case LE; Young SP; Rosenberg AS; Kishnani PS
Genet Med; 2012 Jan; 14(1):135-42. PubMed ID: 22237443
[TBL] [Abstract][Full Text] [Related]
11. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease.
Wang Z; Okamoto P; Keutzer J
Mol Genet Metab; 2014 Feb; 111(2):92-100. PubMed ID: 24044919
[TBL] [Abstract][Full Text] [Related]
12. Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells.
Banugaria SG; Patel TT; Mackey J; Das S; Amalfitano A; Rosenberg AS; Charrow J; Chen YT; Kishnani PS
Mol Genet Metab; 2012 Apr; 105(4):677-80. PubMed ID: 22365055
[TBL] [Abstract][Full Text] [Related]
13. An updated management approach of Pompe disease patients with high-sustained anti-rhGAA IgG antibody titers: experience with bortezomib-based immunomodulation.
Desai AK; Shrivastava G; Grant CL; Wang RY; Burt TD; Kishnani PS
Front Immunol; 2024; 15():1360369. PubMed ID: 38524130
[TBL] [Abstract][Full Text] [Related]
14. HLA- and genotype-based risk assessment model to identify infantile onset pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA).
De Groot AS; Kazi ZB; Martin RF; Terry FE; Desai AK; Martin WD; Kishnani PS
Clin Immunol; 2019 Mar; 200():66-70. PubMed ID: 30711607
[TBL] [Abstract][Full Text] [Related]
15. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.
Van den Hout JM; Kamphoven JH; Winkel LP; Arts WF; De Klerk JB; Loonen MC; Vulto AG; Cromme-Dijkhuis A; Weisglas-Kuperus N; Hop W; Van Hirtum H; Van Diggelen OP; Boer M; Kroos MA; Van Doorn PA; Van der Voort E; Sibbles B; Van Corven EJ; Brakenhoff JP; Van Hove J; Smeitink JA; de Jong G; Reuser AJ; Van der Ploeg AT
Pediatrics; 2004 May; 113(5):e448-57. PubMed ID: 15121988
[TBL] [Abstract][Full Text] [Related]
16. Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease.
van Gelder CM; Hoogeveen-Westerveld M; Kroos MA; Plug I; van der Ploeg AT; Reuser AJ
J Inherit Metab Dis; 2015 Mar; 38(2):305-14. PubMed ID: 24715333
[TBL] [Abstract][Full Text] [Related]
17. Antibodies against recombinant human alpha-glucosidase do not seem to affect clinical outcome in childhood onset Pompe disease.
van Kooten HA; Ditters IAM; Hoogeveen-Westerveld M; Jacobs EH; van den Hout JMP; van Doorn PA; Pijnappel WWMP; van der Ploeg AT; van der Beek NAME
Orphanet J Rare Dis; 2022 Feb; 17(1):31. PubMed ID: 35109913
[TBL] [Abstract][Full Text] [Related]
18. Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease.
Cousens LP; Mingozzi F; van der Marel S; Su Y; Garman R; Ferreira V; Martin W; Scott DW; De Groot AS
Hum Vaccin Immunother; 2012 Oct; 8(10):1459-64. PubMed ID: 23095864
[TBL] [Abstract][Full Text] [Related]
19. Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model.
Joseph A; Munroe K; Housman M; Garman R; Richards S
Clin Exp Immunol; 2008 Apr; 152(1):138-46. PubMed ID: 18307520
[TBL] [Abstract][Full Text] [Related]
20. CRIM-negative infantile Pompe disease: 42-month treatment outcome.
Rohrbach M; Klein A; Köhli-Wiesner A; Veraguth D; Scheer I; Balmer C; Lauener R; Baumgartner MR
J Inherit Metab Dis; 2010 Dec; 33(6):751-7. PubMed ID: 20882352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
